{
  "id": "514a11add24251bc05000054",
  "type": "list",
  "question": "Which diseases can Oncotype DX be used for?",
  "ideal_answer": "Oncotype can be used for predicting breast cancer and colon cancer recurrence.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
    "http://www.ncbi.nlm.nih.gov/pubmed/19101988",
    "http://www.ncbi.nlm.nih.gov/pubmed/19536946",
    "http://www.ncbi.nlm.nih.gov/pubmed/21934103",
    "http://www.ncbi.nlm.nih.gov/pubmed/23074401",
    "http://www.ncbi.nlm.nih.gov/pubmed/18942607",
    "http://www.ncbi.nlm.nih.gov/pubmed/21176237",
    "http://www.ncbi.nlm.nih.gov/pubmed/18347556",
    "http://www.ncbi.nlm.nih.gov/pubmed/22811953",
    "http://www.ncbi.nlm.nih.gov/pubmed/22590486",
    "http://www.ncbi.nlm.nih.gov/pubmed/23371261",
    "http://www.ncbi.nlm.nih.gov/pubmed/21479927",
    "http://www.ncbi.nlm.nih.gov/pubmed/19125125",
    "http://www.ncbi.nlm.nih.gov/pubmed/20200857",
    "http://www.ncbi.nlm.nih.gov/pubmed/18072276",
    "http://www.ncbi.nlm.nih.gov/pubmed/22361999",
    "http://www.ncbi.nlm.nih.gov/pubmed/21278441",
    "http://www.ncbi.nlm.nih.gov/pubmed/21370017",
    "http://www.ncbi.nlm.nih.gov/pubmed/21221771",
    "http://www.ncbi.nlm.nih.gov/pubmed/20877447",
    "http://www.ncbi.nlm.nih.gov/pubmed/20564629"
  ],
  "snippets": [
    {
      "text": "Prognostic and predictive markers",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371261",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Oncotype DX\u00ae currently allow avoidance of an over therapy or under therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23371261",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "a high score on the Oncotype DX gene expression profile r",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22590486",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "poor-prognosis ER-positive breast cancers in need of more aggressive therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22590486",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "luminal B class",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22590486",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The 21-gene recurrence score (Oncotype DX: RS) appears to augment clinico-pathologic prognostication and is predictive of adjuvant chemotherapy benefit in node-negative (N-) and node-positive (N+), endocrine-sensitive breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22361999",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Half of all breast cancers are early stage, lymph node negative, and hormone receptor positive. A 21-gene (Oncotype DX\u00ae; Genomic Health, Inc., Redwood City, CA) recurrence score (RS) is prognostic for recurrence and predictive of chemotherapy benefit.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21934103",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "We hypothesized that a distinct network of immune function genes at the tumor site can predict a low risk versus high risk of distant relapse in breast cancer patients regardless of the status of ER, PR, or HER-2/neu in their tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Real-time RT-PCR confirmed the 5-gene prognostic signature that was distinct from an FDA-cleared 70-gene signature of MammaPrint panel and from the Oncotype DX recurrence score assay panel. These data suggest that neoadjuvant immunotherapy in patients with high risk of relapse may reduce tumor recurrence by inducing the immune function genes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479927",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Molecular tests such as the Oncotype DX(\u00ae) breast cancer test are proving to be more effective tools for individualized patient stratification and treatment planning than traditional methods such as patient demographic variables and histopathology indicators.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21370017",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Node-negative breast cancer does not automatically suggest a good prognosis, or the preclusion of chemotherapy benefits, and additional biomarkers are needed to help identify patients who do benefit from chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278441",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The oncotype DX\u00ae genomic assay has also been used to help prognosis estimation and treatment decisions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21278441",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The Oncotype DX Recurrence Score (RS) is a validated genomic predictor of outcome and response to adjuvant chemotherapy in ER-positive breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21221771",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The 21-gene signature has been intensively studied and incorporated into major guidelines for treatment decision in early breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20564629",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Among early-stage breast cancer patients who received Oncotype DX, we found low knowledge about many aspects of genomic recurrence risk testing.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20200857",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "the gene expression signatures that define specific prognostic subtypes in other breast cancer datasets, such as luminal A and B, basal, normal-like, and ERBB2+, and prognostic signatures including MammaPrint and Oncotype DX, predicted genomic instability in our samples. This remarkable congruence suggests a biological interdependence of poor-prognosis gene signatures, breast cancer subtypes, genomic instability, and clinical outcome.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19101988",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The Oncotype DX assay is one of the molecular tests that provide predictive and prognostic information to breast cancer patients with estrogen receptor (ER)-positive and node-negative disease. This study evaluates the association of Forkhead-box protein A1 (FOXA1) and GATA-binding protein 3 (GATA3) expressions with Oncotype DX recurrences scores in 77 cases of patients with ER-positive node-negative breast carcinomas diagnosed at Indiana University.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19946260",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "the use of the Oncotype DX assay in estrogen receptor-positive node-negative breast cancer patients were incorporated into guidelines from both the American Society of Clinical Oncology and the National Comprehensive Cancer Network. The Oncotype DX assay is a diagnostic test which measures changes in a set of 21 genes in order to predict the likelihood of disease recurrence and also to predict which patients are most likely to respond to chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19536946",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The EWG found adequate evidence regarding the association of the Oncotype DX Recurrence Score with disease recurrence and adequate evidence for response to chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19125125",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "EWG) found insufficient evidence to make a recommendation for or against the use of tumor gene expression profiles to improve outcomes in defined populations of women with breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19125125",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "confirmed the clinical validity of the Oncotype DX breast cancer assay, not only as a way to predict recurrence but also as a tool for determining therapeutic benefit from adjuvant chemotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18347556",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Over several decades, investigators working through National Cancer Institute-sponsored Cooperative Groups have contributed to major advances in the endocrine treatment of breast cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072276",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Cooperative Group studies have contributed to the development of a molecular profiling test, Oncotype Dx, which identifies women who have an excellent prognosis with hormonal therapy alone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18072276",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "In this report we compare the prognostic and predictive utility of these two tools in node-negative, ER-positive breast cancer",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21221771",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The Oncotype-DX Breast Cancer Assay (Genomic Health, Redwood City, CA) quantifies gene expression for 21 genes in breast cancer tissue by performing reverse transcription polymerase chain reaction (RT-PCR) on formalin-fixed paraffin-embedded (FFPE) tumour blocks that are obtained during initial surgery (lumpectomy, mastectomy, or core biopsy) of women with early breast cancer that is newly diagnosed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23074401",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "78 women, treated for early-stage, estrogen receptor-positive breast cancer with 0-3 positive lymph nodes, whose medical records indicated they received Oncotype DX testing earlier.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20200857",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "A retrospective chart review of 58 T1/T2, node-negative, estrogen-receptor positive breast cancer patients that underwent Oncotype DX gene assay testing between January and December 2006 was performed.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18942607",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001941",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003108",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003109"
  ],
  "exact_answer": "breast cancer, colon cancer"
}